FDA approves first Tenosynovial giant cell tumour treatment Turalio (Pexidartinib) The US FDA has given its approval to Turalio (pexidartinib) capsules for the treatment of symptomatic tenosynovial...
Gastroparesis is a condition that affects the movement of the food in the stomach and intestines and causes distress leading to bloating, nausea, and heartburn. If the condition is due to Diabetes in the patients, it is called Diabetic Gastroparesis. According to the American Diabetes Association (ADA), Gastropares...
Find More
EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted...
Find More
Hernia Awareness Month Hernia Awareness Month is observed every year in June to raise public awareness about hernias and effective treatment. The aim is to increase the public knowledge of the warning signs and latest treatment options available for hernias. A hernia occurs when there is a weakness in the wal...
Find More
Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide, also known as LY3298176, has been excellent in reducing body weight and blood sugar in patients with poorly co...
Find More
Earlier in our article, we discussed how mostly off-label therapies so far dominate the NASH therapeutics market. So, let us dig deeper into it and find out what can we expect in the coming years in term of NASH treatments. As we know, there is no approved therapy available for NASH, and many Doctors rely on off-la...
Find More
NASH market share of off label therapies, it will keep on experiencing a steady growth until a standard approved therapy enters the NASH treatment market. Non-alcoholic fatty liver disease (NAFLD), is the most common group of conditions in which there is an excess fat accumulation in the liver in people who i...
Find More
Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology and Market Forecast - 2028 Irritable Bowel Syndrome affects 1 in 5 people and usually develops in the age of 20 to 30 years. Click here to get free sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Irritable-Bowel-Syndrome-(IB...
Find More
Amgen reveals the price of EVENITY Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum or USD 1,825 a month, the bone-building drug was approved by the FDA recently for the treatment of Osteoporosis in postmenopausal women and now will be available i...
Find More
Traveler’s Diarrhea is an intestinal infection, a digestive tract disorder that requires research as globally many tourists are affected by it. According to the United Nations World Tourism Organization, in 2004, around 25%-50% of approximately 34 million international travelers, who visited developing countries, a...
Find More
A rare glomerular kidney-scarring disease, Focal Segmental Glomerulosclerosis (FSGS) is a disease wi.....
Find More
Multiple myeloma (MM) is a cancer of the blood that begins in the bone marrow. In myeloma, plasma ce.....
Find More
Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....
Find More
Progressive Supranuclear Palsy (PSP) is a rare progressive disorder resulting from damage that occur.....
Find More
An autosomal recessive disorder, Ataxia Telangiectasia, affects a person's nervous system, immune sy.....
Find More
Affecting the entire body, Adult Onset Still's disease (AOSD) is a rare type of inflammatory arthrit.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
